Core Viewpoint - Silverno Pharmaceuticals-B (2591.HK) debuted on the Hong Kong Stock Exchange today, opening at HKD 72, a 285.44% increase, with a market capitalization of HKD 32.9 billion [1] Group 1: Company Overview - Silverno Pharmaceuticals was established in 2014 and is a science-driven biopharmaceutical company focused on providing high-quality drugs for patients with metabolic diseases [1] - The company's pipeline includes its core product, Isupatide α, which is under development for the treatment of obesity and overweight, as well as metabolic dysfunction-related fatty liver disease (MASH), along with five other candidates in preclinical stages [1] Group 2: IPO Details - During the offering period, Silverno Pharmaceuticals was oversubscribed by 5,340 times, making it the second highest in oversubscription for new stocks this year, following Bruker at approximately 6,000 times [1] - The net proceeds from the global offering are approximately HKD 610 million, with about 90% allocated for ongoing and planned clinical trials and the commercialization of Isupatide α, while the remainder will be used for working capital and general corporate purposes [1]
港股异动丨“减肥药市场新星”银诺医药-B(2591.HK)首日上市高开285%